Clinical Outcomes of Laser Hemorrhoidoplasty with Feeding Vessels Suture Ligation. A Retrospective Study in a Single Center

Abstract

Background Laser hemorrhoidoplasty has demonstrated significant therapeutic effectiveness. In order to diminish postoperative bleeding and enhance overall outcomes, we have additionally adopted suture-ligating the feeding vessels. This study aimed to investigate patients who underwent this procedure and to better understand the treatment outcomes and any associated complications. Methods This study included 173 patients who had grade II to III symptomatic hemorrhoids and had undergone laser hemorrhoidoplasty with feeding vessels suture ligation between September 1, 2020 and August 31, 2022 consecutively. First, hemorrhoid-feeding vessels located approximately 2 cm above the dentate line were identified by grasping the hemorrhoid tissues. These vessels were then suture-ligated. Subsequently, diode laser shots were administered to each hemorrhoid. Surgical-related information, short-term postoperative pain, discomfort following discharge, hemorrhoid recurrence and any complications were all obtained from inpatient records, outpatient follow-ups, and telephone interviews. Results 173 patients were included in the study. The median pain score at four hours postoperatively was 3. Nine patients (5.2%) experienced bleeding. Six patients (3.5%) developed abscesses. Twelve patients (6.9%) reported a symptomatic recurrence, at an average time of 6.2 months. Three patients (1.7%) still experience a tenesmus sensation, while 6 (3.5%) have had a change in flatulence sensation which has now gradually improved. More than 90% of the patients were satisfied with the results, while 8.7% expressed dissatisfaction. Limitations This was a retrospective study at a single medical center. We cannot obtain long-term follow-up results due to the fact we began this procedure in 2020. Conclusions Laser hemorrhoidoplasty with feeding vessels suture ligation appears to be a promising minimally invasive treatment option for symptomatic grade II and III hemorrhoids.